Purpose of this study is to assess the safety, tolerability, pharmacokinetics,
immunogenicity, and antitumor activity of volrustomig in combination with other
anticancer drugs in participants with specified solid tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT06448754.
Locations matching your search criteria
United States
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer CenterStatus: Approved
Name Not Available
This Phase II, platform, open-label, multicenter study will evaluate the efficacy,
safety, and tolerability of volrustomig in combination with anticancer drugs in various
solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]).
Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Lead OrganizationAstraZeneca Pharmaceuticals LP